Oral Antiviral Therapy is First-Line Treatment
For HSV-1 herpes labialis (cold sores) on the upper lip/mouth, prescribe oral antiviral therapy initiated within 48 hours of symptom onset—preferably during the prodromal stage—using one of these regimens: valacyclovir 2g twice daily for 1 day, famciclovir 1500mg single dose, or acyclovir 400mg three times daily for 5 days. 1, 2
Treatment Algorithm
For Episodic Outbreaks (Most Common Scenario)
First-line oral options (in order of convenience and bioavailability):
Valacyclovir 2g twice daily for 1 day (single-day therapy) 1
- Superior bioavailability compared to acyclovir
- Most convenient dosing schedule
- Reduced median episode duration to 4.0-5.0 days vs 5.0 days with placebo 1
Famciclovir 1500mg as a single dose 3
Acyclovir 400mg three times daily for 3-5 days 4
Critical Timing Consideration
Treatment must begin within 48 hours of lesion onset—ideally during the prodromal stage (tingling/burning sensation before visible lesions) to achieve optimal results. 2, 5 Late initiation significantly reduces efficacy.
For Frequent Recurrences (≥6 episodes/year)
Chronic suppressive therapy:
Evidence shows 53% fewer clinical recurrences with suppressive acyclovir vs placebo, and significantly longer time to recurrence with valacyclovir (13.1 weeks vs 9.6 weeks) 1
Topical Therapy (Secondary Option)
Topical antivirals are less effective than oral therapy but can be considered if oral therapy is contraindicated:
Important caveat: Topical agents are not effective for prevention of recurrent herpes labialis and should only be used for episodic treatment 2
Key Clinical Pitfalls to Avoid
Delayed treatment initiation: Waiting beyond 48 hours dramatically reduces antiviral efficacy 2, 5
Prescribing topical therapy as first-line: Oral antivirals are superior in efficacy, require less frequent dosing, and hasten healing more effectively 2
Underdosing: The evidence supports high-dose, short-course therapy (e.g., valacyclovir 2g twice daily) rather than traditional lower-dose, longer-duration regimens 5
Missing suppressive therapy candidates: Patients with ≥6 episodes/year benefit significantly from daily suppressive therapy but are often not offered this option 2
Special Populations
- Immunocompromised patients: Require longer treatment duration (beyond 3-5 days) and may need prophylactic therapy 2, 6
- Pediatric patients: Acyclovir is the only approved oral antiviral; valacyclovir and famciclovir lack pediatric approval 2
- Patients undergoing facial cosmetic procedures: Prophylactic acyclovir, valacyclovir, or famciclovir prevents HSV-1 reactivation 5
Evidence Quality Note
The guideline evidence 1 from 2012 remains the most comprehensive systematic evaluation of antiviral dosing regimens, showing clear dose-response relationships and optimal treatment durations. More recent reviews 2, 7 confirm these recommendations remain current standard of care, with oral antivirals consistently outperforming topical therapy for both symptom duration and healing time.